Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni P L, Colombo M, Beck-Peccoz P
Istituti di Scienze Endocrine, Medicina Interna-Malattie Infettive-Immunopatologia, Ospedale Maggiore IRCCS, Milan, Italy.
Eur J Endocrinol. 1995 May;132(5):587-93. doi: 10.1530/eje.0.1320587.
The occurrence of thyroid abnormalities and the appearance of organ- and non-organ-specific autoantibodies during long-term recombinant interferon alpha-2a (IFN-alpha) therapy were studied in 86 and 51 consecutive outpatients with hepatitis C and B virus-related chronic active hepatitis (CAH-HCV and CAH-HBV), respectively. Most patients had longstanding community-acquired hepatitis. At baseline, 9.3% of CAH-HCV and 3.9% of CAH-HBV patients showed clinical and/or biochemical signs of thyroid dysfunction. The remaining patients were euthyroid, although anti-thyroid autoantibodies were found in 33/78 (42.3%) of CAH-HCV and in 5/49 (10.2%) of CAH-HBV patients. During IFN-alpha treatment, increased anti-thyroid autoantibody levels were seen in 40% of CAH-HCV initially negative patients, while they became detectable in no more than 10% of CAH-HBV patients. Interferon-alpha-induced hypo- or hyperthyroidism was recorded in 12 of 35 CAH-HCV patients treated for 12 months (34.3%). Only one CAH-HBV patient developed hyperthyroidism. High titers of anti-nuclear autoantibodies (ANA) were recorded at enrollment in 5/36 (13.8%) of CAH-HCV and in 3/16 (18.7%) of CAH-HBV patients. Only one CAH-HCV patient displayed anti-parietal cell antibodies (PCA). After IFN-alpha treatment, ANA were found in 10/28 (35.7%) and PCA in 2/28 (7.1%) of CAH-HCV patients, while an additional CAH-HBV patient developed PCA, but not ANA. However, no signs of systemic autoimmune disease were recorded.(ABSTRACT TRUNCATED AT 250 WORDS)
分别对86例和51例连续门诊的丙型肝炎和乙型肝炎相关慢性活动性肝炎（CAH-HCV和CAH-HBV）患者进行研究，观察长期重组干扰素α-2a（IFN-α）治疗期间甲状腺异常的发生情况以及器官特异性和非器官特异性自身抗体的出现情况。大多数患者患有长期社区获得性肝炎。基线时，9.3%的CAH-HCV患者和3.9%的CAH-HBV患者表现出甲状腺功能障碍的临床和/或生化体征。其余患者甲状腺功能正常，尽管在33/78（42.3%）的CAH-HCV患者和5/49（10.2%）的CAH-HBV患者中发现了抗甲状腺自身抗体。在IFN-α治疗期间，40%最初抗甲状腺自身抗体阴性的CAH-HCV患者抗体水平升高，而在CAH-HBV患者中这一比例不超过10%。在接受12个月治疗的35例CAH-HCV患者中，有12例（34.3%）出现IFN-α诱导的甲状腺功能减退或亢进。只有1例CAH-HBV患者出现甲状腺功能亢进。在入组时，5/36（13.8%）的CAH-HCV患者和3/16（18.7%）的CAH-HBV患者记录到高滴度抗核自身抗体（ANA）。只有1例CAH-HCV患者出现抗壁细胞抗体（PCA）。IFN-α治疗后，28例CAH-HCV患者中有10例（35.7%）出现ANA，2例（7.1%）出现PCA，而另有1例CAH-HBV患者出现PCA，但未出现ANA。然而，未记录到系统性自身免疫性疾病的体征。（摘要截短至250字）
